Azienda Ospedaliera Universitaria Integrata Verona
Quick facts
Phase 3 pipeline
- Tixagevimab Cilgavimab · Infectious disease
Tixagevimab and cilgavimab are monoclonal antibodies that bind to the SARS-CoV-2 spike protein, preventing viral entry into host cells.
Phase 2 pipeline
- Vistabex · Other
Phase 1 pipeline
- Libramed · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Azienda Ospedaliera Universitaria Integrata Verona portfolio CI brief
- Azienda Ospedaliera Universitaria Integrata Verona pipeline updates RSS
Frequently asked questions about Azienda Ospedaliera Universitaria Integrata Verona
What is Azienda Ospedaliera Universitaria Integrata Verona's pipeline?
Azienda Ospedaliera Universitaria Integrata Verona has 1 drugs in Phase 3, 1 in Phase 2, 1 in Phase 1. Late-stage candidates include Tixagevimab Cilgavimab.
Related
- Sector hub: All tracked pharma companies